As Mr. Braid said earlier—and Mr. Masse mentioned it in his question—there is the whole issue of traceability. And this does not necessarily have to do with whether the medication will be returned, but whether it will be distributed elsewhere for commercial purposes. So a drug diversion problem would arise. When the officials appeared before us last week, that is one of the aspects they drew our attention to, saying that Bill C-393 reduces traceability, or does not allow for the traceability of drugs in order to ensure that they are really going where they are supposed to.
Mr. Elliott, in your presentation, you were challenging some of the negative arguments against Bill C-393 made by the officials last week. In your opinion, their warnings to us were not justified. Could you perhaps provide more details on the topic? Could you explain why, in your opinion, officials responsible for the smooth operation of Canada's Access to Medicines Regime, that is the officials responsible for making sure that vulnerable populations have access to drugs, would want to put up roadblocks, so to speak? Why would they be against improving the program, which is designed to ensure that vulnerable populations get the help they need?